Medium supplementation with human, but not fetal calf serum facilitates endocytosis of PLGA nanoparticles by human primary B-lymphocytes via complement opsonization.

[1]  K. Jandt,et al.  Distinct endocytosis and immune activation of poly lactic-co-glycolic acid nanoparticles prepared by single- and double-emulsion evaporation. , 2021, Nanomedicine.

[2]  D. Ricklin,et al.  The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology , 2021, Frontiers in Immunology.

[3]  M. Bros,et al.  Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells , 2021, International journal of molecular sciences.

[4]  Hans-Ulrich Humpf,et al.  Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles , 2019, Beilstein journal of nanotechnology.

[5]  T. Vorup-Jensen,et al.  Structural Immunology of Complement Receptors 3 and 4 , 2018, Front. Immunol..

[6]  S. Tenzer,et al.  Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses , 2018, Journal of Allergy and Clinical Immunology.

[7]  Y. Hagihara,et al.  Heat denaturation of the antibody, a multi-domain protein , 2017, Biophysical Reviews.

[8]  B. Ruozi,et al.  Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles. , 2018, Nanomedicine.

[9]  Jong-Min Lim,et al.  Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics , 2017, Nature Communications.

[10]  Seyed Moein Moghimi,et al.  Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. , 2017, Nature nanotechnology.

[11]  B. Schiøtt,et al.  Structural Basis for Simvastatin Competitive Antagonism of Complement Receptor 3* , 2016, The Journal of Biological Chemistry.

[12]  K. Landfester,et al.  Protein source and choice of anticoagulant decisively affect nanoparticle protein corona and cellular uptake. , 2016, Nanoscale.

[13]  C. Solans,et al.  Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. , 2015, Nanoscale.

[14]  K. Bieback.  Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal Cell Cultures , 2013, Transfusion Medicine and Hemotherapy.

[15]  V. Puntes,et al.  Inorganic nanoparticle biomolecular corona: formation, evolution and biological impact. , 2012, Nanomedicine.

[16]  Katharina Landfester,et al.  Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. , 2011, ACS nano.

[17]  O. Yli-Harja,et al.  Differential gene expression in adipose stem cells cultured in allogeneic human serum versus fetal bovine serum. , 2010, Tissue engineering. Part A.

[18]  Samir Mitragotri,et al.  Role of Particle Size in Phagocytosis of Polymeric Microspheres , 2008, Pharmaceutical Research.

[19]  L. Nagy,et al.  Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. , 2007, Blood.

[20]  W. Jonas,et al.  Conglutination and haemolysis of unsensitized human erythrocytes by bovine serum complement. , 1982, Immunology letters.

[21]  Dirk Strunk,et al.  Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? , 2016, Biomaterials.

[22]  Francesco Salvatore,et al.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. , 2016, Nanomedicine.

[23]  K. Isobe,et al.  Inhibition of human complement-dependent cell lysis by bovine aortic endothelial cells transfected with membrane-bound complement-regulatory factor (DAF and HRF20) gene using a retroviral vector. , 1996, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[24]  L. Vroman,et al.  Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. , 1980, Blood.